Page 341 - ASHG 2013 Program Guide

322  
SPEAKER AND AUTHOR DISCLOSURES
Al-Dewik, N., National Priority Research Program
(
NPRP) Fund, QNRF - 2 (3312W)
Alexander, A. C., Pearlgen - 4 (97)
Andrade, R. V., FAP-DF - 14; CAPES - 2; CNPq - 2
(3488
F)
Angrist, M., NIH - 2; Personalgenomes.org 501(c)(3) -
6;
InVitae - 15; unpaid consultant (Session 5)
Aradhya, S., GeneDx - 3 (206)
Arezi, B., Agilent Technologies - 1, 3 (1672T)
Attri, S., ICMR - 2; PGIMER - 14 (2402F)
Aulchenko, Y., “Yurii Aulchenko” consulting - 4 (1768F)
Baek, R. C., Genzyme - 3 (2293T)
Bainbridge, M. N., Codified Genomics - 13 (2523T)
Bale, S. J., GeneDx/BioReference - 1, 2; Raindance
Technologies - 11; Ingenuity - 11 (Session 37)
Balwani, M., Genzyme - 11, 14 (2274F)
Barber, M. J., AncestryDNA - 3, 1 (1861F)
Bergstrom Lucas, A., Agilent Technologies - 3 (3217F)
Berman, J., Bio-Rad Digital Biology Center - 3 (530W)
Berosik, S., Life Technologies - 3 (1603T)
Biesecker, L., Illumina Corp. - 11; Genentech Corp. - 7;
Wiley-Blackwell - 5 (Session 72)
Billaud, J., Ingenuity - 3 (611W)
Bodamer, O. A., Shire Inc - 2, 5; Genzyme/Sanofi - 8
(
Session 76)
Bodor, J., Czech Genetic Bank - 3, 4 (2308F)
Boles, C., Sage Science, Inc. - 1, 3 (1646F)
Boles, R. G., Courtagen Life Sciences, Inc. - 1, 3 (1343W)
Bowles, K. R., Myriad Genetic Laboratories, Inc. - 1, 3;
Myriad Genetics, Inc. - 1, 3 (1541F)
Breen, C., Shire - 14 (84)
Breman, A., Baylor College of Medicine - 3 (377)
Brenner, S. E., NIH - 2; Tata Consultancy Services - 2
(584
W)
Brun, F., NIH - 2; AHA - 2 (2211W)
Buhay, C. J., DNAnexus - 12 (1437W)
Buis, J. M., aMDx Laboratory Sciences - 1, 3 (2554F)
Bustamante, C. D., Personalis, Inc. - 11; InVitae - 11;
Ancestry.com - 11 (258)
Byrnes, J. K., Ancestry.com DNA L.L.C. - 3 (2059F)
Calley, J., Eli Lilly and Co. - 3, 1 (1438T)
Cantalapiedra, D., Sistemas Genómicos, SL - 3
(2135
F)
Cardona, A., ERC grant - 2 (184)
Chandratillake, G., Personalis, Inc. - 1, 3 (2639W)
Chen, C., Life Technologies - 3 (531T)
Chen, X., Merck - 3 (1942F)
Chennagiri, N., Good Start Genetics - 1, 3 (1619F)
Chitty, L., Illumina Inc - 3, 12 (2855W)
Chu, A. Y., AstraZeneca - PMR and DIC - 2 (698W)
Chu, S., Life Technologies - 3 (3267W)
Cole, C., CIHR - 2 (860F)
Dallaire, S., PerkinElmer - 1, 3 (2846T)
De La Vega, F. M., Real Time Genomics, Inc. - 1, 3;
Real Time Genomics, Ltd. - 1, 3 (1587W)
Demko, Z., Natera, Inc. - 3 (2857W)
De Sarkar, N., CSIR - 2 (3490T)
Dewey, F., Personalis - 1, 5 (236)
Dickson, P., BioMarin - 2; Armagen - 5; Isis
Pharmaceuticals - 5; Shire - 11 (2398F)
Dieterich, K., Fondation Medicale pour la Recherche -
2;
DRCI Grenoble - 2; DRCI Kremlin-Bicetre - 2 (290)
Dufault, M. R., Genzyme Corporation - 3 (89)
Eberle, M. A., Illumina - 1, 3 (200)
Eichler, E. E., Pacific Biosciences, Inc. - 5, 6; SynapDx
Corp. - 6; DNAnexus, Inc. - 6 (Session 71)
Elhaik, E., National Genographic - 2, 11 (1944T)
Elstein, D., Shire HGT - 14; Pfizer - 14 (Session 42)
Emerson, R. O., Adaptive Biotechnologies - 1, 3 (7)
Eriksson, N., 23andMe - 1, 3 (335)
Evans, J. P., NIH - 2; ACMG - 6 (Session 5)
Feenstra, B., Statens Serum Institut - 10 (963W)
Fernandes, Q., National Priority Research Program
(
NPRP) - QNRF - 2 (3455F)
Francke, U., 23andMe - 3; InVitae - 11 (Session 6)
Fritsche, L. G., ArcticDX - 5 (338)
Galvin, B., Nabsys, Inc. - 1, 3 (1588T)
Gandomi, S. K., Ambry Genetics - 3 (2694W)
Garcia, J., InVitae - 3 (2626F)
Garcia, S., Personalis, Inc - 1, 3 (1550F)
Gasparini, N., FAP-DF - 14; CAPES - 2; CNPq - 2
(3494
F)
Geiss, G., NanoString Technologies, Inc - 3 (1636T)
Gener, M. A. H., Akron Children’s Hospital - 3 (2014F)
Germain, D. P., Genzyme - 14; Shire - 14 (2367T)
Gerry, N. P., DNA Genotek - 14 (2576W)
Giang, K., Zymo Research Corporation - 3 (460T)
Glusman, G., Ingenuity Systems - 9 (1453T)
Goker-Alpan, O., Genzyme - 2, 5, 8, 11, 14; Shire
HGT - 2, 5, 8, 11, 14; Amicus - 5; Pfizer - 8, 11, 14
(
Session 42)
Goldstein, D. B., Duke University - 3; NIH - 2, 11;
GlaxoSmithKline - 2; Merck & Co - 10 (Session 40)
Golembo, M., Protalix Biotherapeutics - 3 (2289T)
Gonzalez, K., Ambry Genetics - 3 (1111T)
Gottesfeld, J., Repligen Corporation - 5, 7, 12;
Sangamo Biosciences - 7 (Session 73)
Grabowski, G. A., Genzyme/Sanofi - 5, 2; Shire/HGT -
2, 5, 7;
Pfizer/Protalix - 11; Synageva - 7, 11
(
Session 42)
Granka, J. M., AncestryDNA - 3 (2063W)
Greger, V., Good Start Genetics - 1, 3 (2827W)
Grossman, T. R., ISIS Pharaceuticals - 3; Biogen Idec -
10;
GSK - 10 (2305T)
Hadd, A. G., Asuragen, Inc. - 1, 3 (2497F)
Hagerman, P. J., Pacific Biosciences - 12 (Session 73)
Haller, C., BioMarin Pharmaceutical Inc. - 1, 2, 3, 5, 11,
14 (2290
F)
Hartsfield, J. K., University of Kentucky - 3 (872F)
Hartshorne, T., Life Technologies - 3 (741W)
Haverfield, E., GeneDx, Inc. - 3 (2466T)
Hayashibara, K., Life Technologies - 2, 3 (1668W)
Heaton, W. H., Nabsys - 1, 3, 10 (1601F)
Heckerman, D., Microsoft - 3 (1775W)
Hefner, E., Bio-Rad Laboratories - 3 (541F)
Hegde, M., BioMarin Pharmaceutical Inc. - 1, 2, 3, 5,
8, 11, (2333
T)
Heinrich, V., Deutsche Forschungsgemeinschaft - 2
(1458
W)
Hendel, A., Pacific Biosciences - 12, 14 (201)
Hensel, C., Lineagen, Inc. - 1, 2, 3, 10, 11 (160)
Hermes, K., Edimer Pharmaceuticals, Inc. - 2 (2271T)
Hilbush, B., Real Time Genomics - 3 (3057T)
Hinds, D., 23andMe, Inc. - 1, 3 (921W)
Hirsch, J., Syapse - 3, 4 (1607F)
Hoglund, B. N., Roche Molecular Systems - 3 (2842T)